About the company
Enlivex Therapeutics Ltd, an Israel-based development-stage biopharmaceutical company, is at the forefront of innovative research and development in the field of immunotherapy. With a core focus on rebalancing immune hyper-responses, the company is dedicated to developing and commercializing an allogeneic drug pipeline that has the potential to revolutionize the treatment of life-threatening unbalanced immune systems. In particular, Enlivex's flagship product, Allocetra, is a groundbreaking immunotherapy that shows great promise in addressing the inherent challenges associated with immune dysregulation. The therapy leverages the immune system's own natural regulation mechanisms to restore balance and prevent complications arising from overactive or uncontrolled immune responses. The unique approach of Allocetra lies in its allogeneic nature, meaning it is derived from a donor rather than the patient's own cells. This allows for a more streamlined and readily available treatment option, bypassing the lengthy and complex process of individual patient cell manipulation. By harnessing the power of these allogeneic cells, Enlivex aims to deliver a safe, effective, and scalable solution that can cater to a wide range of patients in need. The underlying science behind Allocetra revolves around the concept of rebalancing immune hyper-responses. In certain conditions, such as severe sepsis, graft versus host disease (GVHD), or organ rejection, the immune system can go into an extreme hyperactive state, leading to devastating consequences for the patient. Enlivex's therapy steps in to modulate these excessive immune responses by activating regulatory T cells (Tregs), which act as vital regulators of the immune system. By introducing these specialized cells, Allocetra works synergistically with the body's existing immune system, ultimately restoring equilibrium and preventing the life-threatening impacts of an unbalanced immune response. Enlivex's dedication to advancing immunotherapy is evident in its extensive clinical development program for Allocetra. The company has initiated several clinical trials across various indications, aiming to solidify the therapy's safety and efficacy profile. By closely monitoring patient outcomes, Enlivex can continually refine the administration protocol and ensure the optimized use of Allocetra in real-world scenarios. The potential impact of Allocetra extends not only across different medical conditions but also across a diverse patient population. Enlivex's commitment to inclusivity means that they are actively exploring the therapy's applicability in various settings, including pediatric patients, elderly individuals, and those with compromised immune systems. This patient-centric approach ensures that Allocetra holds promise as a versatile and accessible treatment option for a wide range of individuals battling unbalanced immune responses. In addition to the clinical development efforts, Enlivex is also focused on building strategic collaborations and partnerships to accelerate the commercialization of Allocetra worldwide. This collaborative approach allows the company to tap into the expertise and resources of industry leaders, ensuring that this groundbreaking immunotherapy reaches patients who need it most, irrespective of geographic boundaries. Enlivex Therapeutics Ltd's pioneering work in the field of immune regulation has the potential to transform the landscape of immunotherapy and revolutionize patient care for those suffering from unbalanced immune responses. With Allocetra at the forefront, Enlivex is poised to make significant strides in mitigating the impact of life-threatening immune dysregulation, ultimately improving the quality of life for patients worldwide.
Website: https://www.enlivex.com
Data updated: June 2, 2026
